SIGA

SIGA Technologies, Inc. - 10-K Summary (Fiscal Year Ended Dec 31, 2006)

Business Context and Reporting Period

This Annual Report covers the fiscal year ended December 31, 2006. SIGA Technologies, Inc. is a biotechnology corporation focused on discovering, developing, and commercializing novel anti-infectives, antibiotics, and vaccines, with a primary emphasis on defense against biological warfare agents such as Smallpox and Arenaviruses. The Company has no commercial products and relies on government grants, contracts, and equity financing to fund operations.

Key Financial Metrics

Note: Long-term obligations in 2006 include $4.67 million classified as common stock warrants liabilities under EITF 00-19.

Material Changes vs. Prior Period

• Revenue Decline: Revenues decreased 14% to $7.26 million from $8.48 million in 2005. This was primarily due to the expiration of certain NIH SBIR grants ($3.5 million decline) partially offset by increased revenue from a USAMRMC contract ($1.8 million increase) and new USAF contracts.
• Increased Operating Loss: Operating loss widened to $6.81 million from $2.53 million. Drivers included a $1.2 million decline in revenue, $1.2 million in professional fees related to a terminated merger with PharmAthene, and increased non-cash expenses (depreciation, amortization, and share-based compensation).
• Liquidity Improvement: Cash and cash equivalents increased significantly from $1.77 million to $10.64 million. This was driven by $8.4 million in net proceeds from a private placement of common stock and warrants in October 2006, and $4.3 million from the exercise of options and warrants.
• Accounting Changes: The Company adopted SFAS 123(R) in 2006, recognizing $471,000 in share-based compensation expense, compared to negligible amounts in 2005 under the previous intrinsic value method.

Guidance, Outlook, Risks, and Unusual Items

• Outlook: Management expects to continue incurring operating losses for the foreseeable future. The Company believes existing cash and anticipated government funding are sufficient to support operations beyond the next twelve months. No commercial products are expected for one to three years.
• Key Developments:
  • Received a $16.5 million, 3-year NIH contract and a $4.8 million SBIR grant for the lead smallpox drug candidate, SIGA-246.
  • Received a $6.0 million, 3-year NIH grant for Lassa fever virus antiviral development.
  • Completed Phase I clinical safety study for SIGA-246; FDA granted Orphan Drug designation in December 2006.
• Risks:
  • Legal Proceedings: PharmAthene, Inc. filed a lawsuit in December 2006 seeking a license for SIGA-246 and damages following the termination of a merger agreement. SIGA intends to defend vigorously.
  • Funding Dependency: Substantially all revenue is derived from government grants and contracts, which can be cancelled for non-performance.
  • Development Risk: High risk of failure in clinical trials and regulatory approval for all product candidates.
• Unusual Items: A $3.09 million loss was recorded in 2006 due to the increase in the fair market value of common stock rights and warrants classified as liabilities. This was a non-cash charge.

Investor Verification Checklist

• Legal Status: Verify the current status and potential financial impact of the PharmAthene, Inc. lawsuit regarding the SIGA-246 license obligation.
• Grant Sustainability: Confirm the renewal status of the NIH SBIR grants and contracts that expired or are expiring, as they constitute the majority of revenue.
• Cash Burn Rate: Assess the runway of the $10.6 million cash balance against the projected $15-$20 million cost to complete the SIGA-246 program.
• Derivative Liabilities: Review the valuation assumptions for the common stock warrants classified as liabilities, as fluctuations in stock price directly impact net loss.
• Clinical Progress: Monitor the results of the ongoing Phase I clinical trials for SIGA-246 (21-day dosing) and any regulatory feedback from the FDA.